

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128712 A1

(51) International Patent Classification:

A61K 31/5377 (2006.01) A61P 27/02 (2006.01)
A61K 45/06 (2006.01) A61K 9/00 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/059586

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

11 December 2024 (11.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/609,230 12 December 2023 (12.12.2023) US

(71) Applicant: CELCUITY INC. [US/US]; 16305 36th Ave
N. Ste 100, Minneapolis, MN 55446 (US).

(72) Inventors: LAING, Lance, Gavin; 16305 36th Ave N. Ste
100, Minneapolis, MN 55446 (US). MACNEIL, Ian; 23
Oak Road, Milton, MA 02186 (US). SULLIVAN, Brian,
Francis; 16305 36th Ave N. Ste 100, Minneapolis, MN
55446 (US).

(74) Agent: REMILLARD, Jane, E. et al.; Nelson Mullins Ri-
ley & Scarborough LLP, One Financial Center, Suite 3500,
Boston, MA 02111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: TREATMENT OF OCULAR DISEASES USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBON
YL)PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA

(57) Abstract: Provided are methods of treating an ocular disease (e.g., neovascular age-related macular degeneration, age-related macular degeneration, diabetic macular edema, choroidal neovascularization (including myopic choroidal neovascularization (mCNV), angioid streaks, choroiditis (including choroiditis secondary to ocular histoplasmosis), idiopathic degenerative myopia, retinal dystrophies, rubeosis iridis, pseudoxanthoma elasticum, and trauma), macular edema following retinal vein occlusion, central retinal vein occlusion, cystoid macular edema, glaucoma (e.g., neovascular glaucoma), polypoidal choroidal vasculopathy, retinopathy of prematurity, ocular von Hippel Lindau disease lesions, diabetic retinopathy, and retinitis pigmentosa) in a human patient by administering to the patient gedatolisib, or a pharmaceutically acceptable salt, solvate, or ester thereof, in an amount and with a frequency sufficient to treat the ocular disease.

WO 2025/128712 A1